http://orcid.org/0000-0001-9220-3910
References
- Hsia SH. Modern pharmacotherapies for type 2 diabetes mellitus. J Natl Med Assoc 2001;93:335-48
- American Diabetes Association. Strategies for improving care. Sec. 1. In Standards of Medical Care in Diabetes - 2015. Diabetes Care 2015;38(Suppl1):S5-S7
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
- Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract 2013;19(Suppl2):1-48
- Diamant M, Nauck MA, Shaginian R, et al. Glucagon-like peptide-1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 2014;37:2763-73
- Crawford AG, Cote C, Couto J, et al. Prevalence of obesity, type II diabetes mellitus, hyperlipidemia, and hypertension in the United States: findings from the GE Centricity Electronic Medical Record database. Popul Health Manag 2010;13:151-61
- Crawford AG, Cote C, Couto J, et al. Comparison of GE centricity electronic medical record database and national ambulatory medical care survey findings on the prevalence of major conditions in the United States. Popul Health Manag 2010;13:139-50
- Charlson ME, Charlson RE, Peterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008;61:1234-40
- Pawaskar M, Li Q, Hoogwerf BJ, et al. Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States. Endocr Pract 2012;18:700-11
- Dalal MR, Xie L, Baser O, et al. Adding rapid-acting insulin or GLP-1 receptor agonist to basal insulin: outcomes in a community setting. Endocr Pract 2015;21:68-76
- Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
- Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-12
- DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
- Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
- Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30:1448-60
- Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-85
- American Diabetes Association Standards of medical care in diabetes-2017 abridged for primary care providers. Clin Diabetes 2017;35:5-26
- Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA 2011;305:1790-9